





# Recombinant Mouse Microtubule-associated protein tau (Mapt) (Active)

<b>Product Code</b>	CSB-MP013481MO
Abbreviation	Recombinant Mouse Mapt protein (Active)
Storage	The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself. Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Uniprot No.	P10637
Form	Lyophilized powder
Storage Buffer	Lyophilized from a 0.2 $\mu m$ filtered 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0
Product Type	Recombinant Protein
Immunogen Species	Mus musculus (Mouse)
Biological Activity	Measured by its binding ability in a functional ELISA. Immobilized Mouse Mapt at 2 $\mu$ g/mL can bind anti-MAPT recombinant antibody (CSB-RA013481A1HU),the EC <sub>50</sub> is 436.1-518.6 ng/mL.
Purity	Greater than 90% as determined by SDS-PAGE.
Sequence	ADPRQEFDTMEDHAGDYTLLQDQEGDMDHGLKESPPQPPADDGAEEPGSET SDAKSTPTAEDVTAPLVDERAPDKQAAAQPHTEIPEGITAEEAGIGDTPNQED QAAGHVTQGRREGQAPDLGTSDWTRQQVSSMSGAPLLPQGLREATCQPSG TRPEDIEKSHPASELLRRGPPQKEGWGQDRLGSEEEVDEDLTVDESSQDSPP SQASLTPGRAAPQAGSGSVCGETASVPGLPTEGSVPLPADFFSKVSAETQAS QPEGPGTGPMEEGHEAAPEFTFHVEIKASTPKEQDLEGATVVGVPGEEQKAQ TQGPSVGKGTKEASLQEPPGKQPAAGLPGRPVSRVPQLKARVASKDRTGND EKKAKTSTPSCAKAPSHRPCLSPTRPTLGSSDPLIKPSSPAVSPEPATSPKHVS SVTPRNGSPGTKQMKLKGADGKTGAKIATPRGAASPAQKGTSNATRIPAKTTP SPKTPPGSGEPPKSGERSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVV RTPPKSPSASKSRLQTAPVPMPDLKNVRSKIGSTENLKHQPGGGKVQIINKKL DLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGG GQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTD HGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQG L
Source	Mammalian cell
Target Names	Mapt
Expression Region	2-733aa
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Tag Info	N-terminal 10xHis-tagged

#### **CUSABIO TECHNOLOGY LLC**







# Mol. Weight

#### 78.9 kDa


#### **Protein Length**

## Full Length of Mature Protein

### **Image**



(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.



# Activity Measured by its binding ability in a functional ELISA. Immobilized Mouse Mapt at 2 µg/ml can

bind anti-MAPT recombinant antibody (CSB-RA013481A1HU), the EC<sub>50</sub> is 436.1-518.6 ng/mL.

## Description

This recombinant mouse Mapt protein (amino acids 2-733) represents the fulllength mature form of this crucial neuronal protein, expressed in mammalian cells with an N-terminal 10×His tag. The recombinant Mapt protein demonstrates high purity (>90% by SDS-PAGE) and minimal endotoxin contamination (<1.0 EU/µg, LAL method), making it suitable for sensitive neurological research applications.

Functional validation through ELISA confirms its specific binding capability to anti-Mapt antibody (CSB-RA013481A1HU) with an EC<sub>50</sub> range of 436.1-518.6 ng/mL when immobilized at 2 μg/mL. The mammalian expression system ensures proper post-translational modifications and folding characteristics critical for maintaining Mapt's native biological functions.

Presented as lyophilized powder, this protein offers excellent stability and convenient handling. The N-terminal 10×His tag facilitates purification without interfering with functional domains. This preparation is particularly valuable for Alzheimer's disease and tauopathy research, microtubule dynamics studies, neurodegenerative disease modeling, and therapeutic development for taurelated disorders.

The mouse Mapt protein, encoded by the Mapt gene, is a crucial component of the microtubule-associated protein family and specifically encodes the Tau protein. This protein plays a significant role in stabilizing microtubules, which are essential for maintaining cellular structure and intracellular transport within

#### **CUSABIO TECHNOLOGY LLC**







neurons [1]. In various studies, Mapt has been implicated in several neurodegenerative diseases, most notably tauopathies, which include conditions such as Alzheimer's disease (AD) and frontotemporal dementia (FTD) [2].

Transgenic mouse models that express various human Mapt mutations, such as the P301L mutation, have been instrumental in elucidating the pathogenic mechanisms underlying tauopathies [3]. For instance, P301L transgenic mice exhibit characteristic neurofibrillary tangles and cognitive deficits that parallel findings in human patients with tauopathies [4]. Additionally, the manipulation of Mapt expression in these models has revealed insights into synaptic dysfunction and impaired glutamate dynamics, linking Mapt expression levels to neurodegenerative processes [3][5].

Furthermore, studies indicate that the absence or downregulation of Mapt can influence neuroinflammatory responses as well as neuronal excitability. For instance, Mapt deletion in specific mouse models has been shown to mitigate certain forms of epilepsy and hyperexcitability, suggesting a complex role for Tau in modulating neuronal activity beyond mere structural support [6]. This aspect of Mapt research highlights its potential as a therapeutic target; studies have indicated that reducing Mapt expression may protect against cognitive deficits associated with Alzheimer's disease in mouse models [2][7].

The diversity of isoforms produced by the Mapt gene due to alternative splicing results in different tau protein variants that can exhibit distinct biological properties and functions [8]. These differences are critical when considering the pathological roles of tau in various tauopathies, as certain isoforms may be more prone to aggregation and, therefore, more detrimental to neuronal health [9].

#### References:

- [1] I. Avitan, Y. Halperin, et al. Towards a consensus on alzheimer's disease comorbidity? Journal of Clinical Medicine, vol. 10, no. 19, p. 4360, 2021. https://doi.org/10.3390/jcm10194360
- [2] X. Da, S. Besselink, et al. Programmable epigenome editing by transient delivery of crispr epigenome editor ribonucleoproteins. 2024. https://doi.org/10.1101/2024.11.26.625496
- [3] R. Crescenzi, C. DeBrosse, et al. Longitudinal imaging reveals subhippocampal dynamics in glutamate levels associated with histopathologic events in a mouse model of tauopathy and healthy mice. Hippocampus, vol. 27, no. 3, p. 285-302, 2017. https://doi.org/10.1002/hipo.22693
- [4] M. Fernández?Nogales, M. Santos?Galindo, et al. Tau?positive nuclear indentations in p301s tauopathy mice. Brain Pathology, vol. 27, no. 3, p. 314-322, 2016. https://doi.org/10.1111/bpa.12407
- [5] C. Chen, J. Holth, et al. mapt deletion fails to rescue premature lethality in two models of sodium channel epilepsy. Annals of Clinical and Translational Neurology, vol. 5, no. 8, p. 982-987, 2018. https://doi.org/10.1002/acn3.599 [6] J. Hull, H. O'Malley, et al. Excitatory and inhibitory neuron defects in a mouse model of scn1b?linked eiee52. Annals of Clinical and Translational Neurology, vol. 7, no. 11, p. 2137-2149, 2020. https://doi.org/10.1002/acn3.51205 [7] T. Taniguchi, N. Doe, et al. Transgenic mice expressing mutant (n279k)





Tel: +1-301-363-4651
Email: cusabio@cusabio.com
Website: www.cusabio.com





human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. Febs Letters, vol. 579, no. 25, p. 5704-5712, 2005. https://doi.org/10.1016/j.febslet.2005.09.047

[8] Y. Pan, Y. Pan, Y. Cheng, F. Yang, Z. Yao, & O. Wang Knockdown of Incrna mapt-as1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating mapt expression in er-negative breast cancers. Cell & Bioscience, vol. 8, no. 1, 2018. https://doi.org/10.1186/s13578-018-0207-5 [9] T. Müller, A. Schrötter, et al. Sense and nonsense of pathway analysis software in proteomics. Journal of Proteome Research, vol. 10, no. 12, p. 5398-5408, 2011. https://doi.org/10.1021/pr200654k

# **Endotoxin** Less than 1.0 EU/ug as determined by LAL method. Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference. Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself. Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life

of lyophilized form is 12 months at -20°C/-80°C.